This report evaluates the clinical validity and clinical utility of the Cxbladder Detect test (Pacific Edge Ltd.).
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Spring Distraction System (Cresco Spine) for Early Onset Scoliosis
The Spring Distraction System (Cresco Spine) is an investigational, growth-friendly implant in development for the treatment of early onset scoliosis (EOS). It is designed to provide continuous distraction and avoid the need for repeated lengthening procedures as the patient grows.
Palovarotene (Sohonos; Ipsen Biopharmaceuticals Inc.) for Fibrodysplasia Ossificans Progressiva
Palovarotene (Sohonos; Ipsen Biopharmaceuticals Inc.) is an oral retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for female persons and 10 years and older for male persons with fibrodysplasia ossificans progressiva.
FoundationOne Heme (Foundation Medicine Inc.)
This report evaluates the clinical validity and clinical utility of the FoundationOne Heme test.
Avasopasem Manganese (Galera Therapeutics Inc.) for Radiotherapy-induced Oral Mucositis
Avasopasem manganese (Galera Therapeutics Inc.) is an investigational intravenous superoxide dismutase mimetic intended to reduce the incidence and severity of radiation-induced oral mucositis in patients undergoing radiotherapy for head and neck cancer.
Nirsevimab-alip (Beyfortus; AstraZeneca and Sanofi) to Prevent Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus
Nirsevimab-alip (Beyfortus; AstraZeneca) is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
NavDx (Naveris)
This report evaluates the clinical validity and clinical utility of the NavDx test.
AccuCinch Ventricular Restoration System (Ancora Heart Inc.) for Heart Failure
The AccuCinch Ventricular Restoration System (Ancora Heart Inc.) is a transcatheter left ventricular cinching device proposed for treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).
Vectra (Laboratory Corporation of America Holdings)
This report evaluates the clinical validity and clinical utility of the Vectra test (Laboratory Corporation of America Holdings).
Cxbladder Monitor (Pacific Edge Ltd.)
This report evaluates the clinical validity and clinical utility of the Cxbladder Monitor test.